Abeona Therapeutics
ABEO
93 hedge funds and large institutions have $464M invested in Abeona Therapeutics in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 9 closing their positions.
200% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 9
42% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 24
39% more capital invested
Capital invested by funds: $335M → $464M (+$130M)
24% more funds holding
Funds holding: 75 → 93 (+18)
0.56% more ownership
Funds ownership: 1.95% → 2.5% (+0.56%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
28% less call options, than puts
Call options by funds: $4.63M | Put options by funds: $6.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$64.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$31.7M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$29.8M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$23.6M |
| 2 |
PC
PointState Capital
New York
|
-$6.45M |
| 3 |
Barclays
London,
United Kingdom
|
-$2.98M |
| 4 |
CHP
Castle Hook Partners
New York
|
-$2.97M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.83M |
ABEO Hedge Fund Activity: Q4 2017 in Review
93 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q4 2017, worth a combined $464M — up 39% from $335M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ABEO positions and 9 closed out — a net gain of 18 holders — while 34 added to existing stakes and 24 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $64.6M. The largest seller was Citadel Advisors, cutting an estimated $23.6M.
- 93 institutional investors held Abeona Therapeutics (ABEO) as of Q4 2017, up from 75 in Q3 2017.
- Funds reported $464M of Abeona Therapeutics stock for Q4 2017, up 39% quarter-over-quarter.
- 27 funds opened new Abeona Therapeutics positions in Q4 2017 and 9 closed out, a net change of +18 holders.
- The largest Abeona Therapeutics buyer in Q4 2017 was Fidelity Investments, an estimated $64.6M added.
- The largest Abeona Therapeutics seller in Q4 2017 was Citadel Advisors, an estimated $23.6M sold.
Based on aggregated 13F filings for Q4 2017.